Celator Pharmaceuticals — Investor Day (July 2015)
132 slides from Celator Pharmaceuticals's investor day presentation, Jul 16, 2015
Slide 1: Transforming the Science of Combination Therapy to Improve Patient Outcomes in Cancer
1 NASDAQ:CPXX | celatorpharma.com Transforming the Science of Combination Therapy to Improve Patient Outcomes in Cancer July 16, 2015 Celator Pharmaceuticals May 28, 2015 © Copyright 2015 Celator Pharmaceuticals. All rights reserved.
Slide 2: Welcome and Introductions
Welcome and Introductions Scott Jackson Chief Executive Officer
Slide 3: Celator Corporate Overview
Option 2 with people Celator Photography Celator Pharmaceuticals 3 Celator Corporate Overview Our mission is to improve and extend the lives of patients with cancer by transforming the science of combination therapy
Slide 4: Safe Harbor
Safe Harbor Celator Pharmaceuticals 4 To the extent that statements contained in this presentation are not descriptions of historical facts regarding Celator, they are forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisio
Slide 5: Agenda
Agenda Celator Pharmaceuticals 5 9:00am - 9:15am Welcome and Introductions Scott Jackson Chief E xecutive Officer 9:15am - 9:30am Overview and Update on CPX - 351 Studies Arthur Louie, MD Chief Medical Officer 9:30am - 9:50am AML Therapy: A GIANT Unmet Need Gail Roboz, MD Cornell University – Weill
Slide 6: Agenda
Agenda Celator Pharmaceuticals 6 11:00am - 11:20am Challenges and Opportunities for Developing Combinations of Molecularly Targeted Agents Anthony Tolcher , MD South Texas Accelerated Research Therapeutics 11:20am - 11:40am CombiPlex Technology Platform: Application to Molecularly Targeted Agent Com
Slide 7: Key Value Drivers
Key Value Drivers • CPX - 351: Late - stage, lead CombiPlex ® - based product • First available data, induction response rate, from a Phase 3 study produced a 43% relative improvement in favor of CPX - 351 over the current standard of care, the 7+3 regimen • Primary endpoint, overall survival, is ex
Slide 8: Reaction to Induction Response Rate
Reaction to Induction Response Rate • Thought - leader feedback has been very positive: • “Impressive CR rate…you beat 7+3 again” • “Response rate is the best surrogate available for clinical benefit” • “Results are favorable…I’ll take it anytime” • “…optimism is justified based on this secondary en
Slide 9: Exciting Future for Celator
Exciting Future for Celator Establishing CPX - 351 as a new foundation of care for AML patients • Phase 3 study - going head - to - head against the 7+3 regimen • Preparing for a NDA submission in 3Q2016 • Commercialization activities are underway • Expanding clinical development to demonstrate broa
Slide 10: Track Record of Delivering on Milestones: CPX-351
Track Record of Delivering on Milestones: Since Analyst and Investor Day 2014 10 Celator Pharmaceuticals CPX - 351 Milestone Projected Achieved Phase 3 Study Achieve Target Enrollment 4Q2014 October 2014 DSMB review of first 225 patients randomized 4Q2014 December 2014 Fast Track Designation 1Q2015
Slide 11: Track Record of Delivering on Milestones: Publications/Presentations
11 Celator Pharmaceuticals CPX - 351 Milestone Projected Achieved Publications/Presentations Ongoing Acute Lymphoblastic Leukemia (ALL) preclinical data published in Pediatric Blood & Cancer September 2014 Presented at the American Association of Pharmaceutical Scientists October 2014 Presented CPX
Slide 12: Track Record of Delivering on Milestones: General
12 Celator Pharmaceuticals General Milestone Achieved Financing Raised capital to now fund activities to NDA submission October 2014 Announced NJEDA program resulted in >$1.9M January 2015 LLS amended agreement and increased milestone payment for induction response rate to $900K June 2015 Intellectu
Slide 13: Upcoming Milestones
Upcoming Milestones • CPX - 351 milestones on path to approval and commercialization: • 1Q2016 - Phase 3 – Overall Survival • 3Q2016 - NDA submission • 1Q2017 - MAA submission • 2Q2017 - FDA Approval • 1Q2018 - EMA Approval • Technology Platform milestones: • 3Q2015 - Data packages on novel combinat
Slide 14: Welcome and Introductions: Arthur Louie, MD
Welcome and Introductions Arthur Louie, MD Chief Medical Officer
Slide 15: CPX-351: Clinical Development
CPX - 351: Clinical Development Celator Pharmaceuticals 15 Phase 1 • Safety and Dose - finding • MTD 100 units/m 2 • Myelosuppression > other Aes • Very encouraging activity Phase 2 • Newly Diagnosed AML 60 - 75y “ 204 Study” • Randomized, controlled study • High - risk – strong signal • Safety • Fi
Slide 16: CPX-351 Phase 3 Study Design in High-Risk AML
CPX - 351 Phase 3 Study Design in High - Risk (e.g. Secondary) AML • Patients were stratified based on age and AML type • Primary Endpoint: Overall survival • > 90% power for HR = 0.635 or better (Observed Phase 2 sAML HR=0.40, p=0.004*) • Secondary Endpoints: Leukemia clearance rate, response rate
Slide 17: What Patients Are Considered High-Risk for the Phase 3 Study?
What Patients Are Considered High - Risk for the Phase 3 Study? Celator Pharmaceuticals 17 The Phase 3 study included the following types of patients: • Treatment – related AML • AML with documented history of MDS with prior treatment with hypomethylating agents • AML with documented history of MDS
Slide 18: CPX-351 Phase 3 Study Update
CPX - 351 Phase 3 Study Update Celator Pharmaceuticals 18 Induction Response Rate • Final analysis of Induction Response Rate ( CR+CRi ), a secondary endpoint in the study • B reakout of CR vs. CRi will be available at the end of the study • Discussed with FDA for impact • Prospectively described in
Slide 19: Phase 3 Study Balanced on Demographics and AML Type
CPX - 351 Phase 3 study is w ell b alanced b ased on patient d emographics and AML t ype Celator Pharmaceuticals 19 CPX - 351 n=153 (%) 7+3 n=156 (%) Total n=309 (%) Gender Male 94 (60.3) 96 (61.5) 190 (61.5) Race Caucasian 128 (83.7) 139 (89.1) 267 (86.4) Age Group ≥70 years 57 (37.3) 54 (34.6) 91
Slide 20: Third Randomized Trial Showing Response Improvement
Third randomized, controlled trial to show a response improvement for CPX - 351 over a cytarabine & anthracycline - based control Celator Pharmaceuticals 20 • Impressive 43% relative improvement in induction response rate • Response is the best available surrogate for overall survival and clinical b
Slide 21: Response Correlation with Overall Survival
Response Correlation with Overall Survival Celator Pharmaceuticals 21 • Response is the best available surrogate for overall survival and clinical benefit • It is not the only factor as overall survival is impacted by early mortality, duration of response, etc. • Walter et al (2010) - MD Anderson Ca
Slide 22: Response Correlates with Overall Survival: Phase 2 Study
Response Correlates with Overall Survival: CPX - 351 Phase 2 Study in Newly Diagnosed AML Patients Celator Pharmaceuticals 22 Lancet et al, ASH 2012 Overall Survival Variable n/N (%) HR (95% CI) P - value Univariate Previous AHD 49/126 (39%) 1.65 (1.01, 2.70) 0.044 High overall risk 84/122 (69%) 1.9
Slide 23: Response Assessment Used in Phase 2 Compared to Phase 3
Response Assessment Used in Phase 2 Compared to Phase 3 Phase 2 Principal Investigator Based on Cheson , et. al. 2003 Phase 3 Independent Reviewer Based on Dohner , et al. 2010 Bone Marrow Assessment • <5% blasts • Absence of Auer rods Same Peripheral blood • ANC ≥1000/mL • Platelets ≥100,000/mL • V
Slide 24: Applying Phase 3 Criteria to Phase 2 Population
Applying Phase 3 Criteria to Phase 2 Population *Phase 2 patient response using the RBC transfusion rules and the 14 - day window requirement for peripheral blood counts. Celator Pharmaceuticals 24 CPX - 351 n=39 7+3 n=19 Relative Improvement Phase 2 criteria Remission Rate (CR+CRi) 73.7% 42.1% 75.1
Slide 25: Summary
Summary • Terrific progress in Phase 3 Study • Impressive 43% relative improvement in Induction Response Rate • Overall survival, the primary endpoint of the study, is expected in 1Q2016 • Other required studies for NDA are on track • NDA projected in 3Q2016 • Broad development incorporating Investi
Slide 26: Clinical Development Strategy for Unmet Need in AML
Clinical Development Strategy is Designed to Explore Important Areas of Unmet Need in AML and other Hematologic Malignancies Celator Pharmaceuticals 26 RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL High Risk (e.g. secondary) Acute Myeloid Leukemia age 60 and ≤75 years (enrolled) Registration
Slide 27: AML Therapy: A GIANT Unmet Need
Gail J. Roboz, M.D. Director, Leukemia Program Professor of Medicine AML Therapy: A GIANT Unmet Need
Slide 28: Acute Myeloid Leukemia
Acute Myeloid Leukemia • Most common acute leukemia in adults • 2015 ≈ 20,800 cases with 10,460 deaths • Median age at diagnosis ≈ 70 • Associated with chemo +/ - radiation exposure, antecedent hematologic disorders, environmental factors • Dangerous and difficult - to - treat disease, progress is l
Slide 29: What Happens in AML?
What Happens in AML? • Bone marrow is the factory that makes blood cells • You need a working bone marrow to live • Abnormal white blood cells (blasts) take over marrow • May have no symptoms, abnormal blood counts picked up on screening • More commonly signs/symptoms of bone marrow failure: infecti
Slide 30: Treatment Options for Older Patients with AML
Treatment Options for Older Patients with AML • Intensive chemotherapy ( “7+3”) • Low - intensity chemotherapy (low - dose cytarabine, decitabine, azacitidine) • Clinical trials (the best option) • Supportive care • No treatment/hospice
Slide 31: AML in Older Adults: Prognostic Model
CR, complete response. Kantarjian et al, 2006. AML in Older Adults: Prognostic Model Prognostic Factor CR Rate 8 - wk Mortality 1 - y Survival Age ≥75 y ■ ■ ■ Poor performance status ■ ■ ■ Unfavorable karyotype ■ ■ ■ Anemia ■ Leukocytosis ■ Antecedent hematologic disease ■ ■ ■ Creatinine >1.3 mg/dL
Slide 32: Secondary AML
Secondary AML • Therapy related AML: history of prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease • AML with a history of myelodysplasia or CMMoL • Different disease biology (characteristic molecular signature) • Associated with unfavorable prognosis and needs allo transplant
Slide 33: What does it mean to be fit for chemo?
What does it mean to be “ fit ” for chemo?
Slide 34: Fit for chemo
Fit for chemo • 75 y/o math professor
Slide 35: Fit for chemo?
? Fit for chemo • 75 y/o homeless man
Slide 36: Separated by minutes
Separated by 5 minutes Weill Cornell Medical College
Slide 37: AML has a dismal prognosis in patients >60 years
AML has a dismal prognosis in patients >60 years. (All lectures, manuscripts, grants and FDA submissions involving elderly AML begin and/or end with this statement.)
Slide 38: Survival of Newly Diagnosed AML
Age ≤ 60 1.0 Year Probability 25 1973 - 1982 1984 - 1990 1990 - 1999 2002 - 2008 n=2,441 0.8 0.6 0.4 0.2 0 20 15 10 5 0 Age > 60 n=1,528 1.0 Probability 0.8 0.6 0.4 0.2 0 0 Year 25 20 15 10 5 1973 - 1982 1984 - 1990 1990 - 1999 2002 - 2008 Survival of Newly Diagnosed AML Consecutive ECOG Frontline T
Slide 39: MDACC: AML Survival by Decade
1.0 0.8 0.6 0.4 0.2 0.0 0 1 2 3 4 5 6 7 8 Proportion Surviving Years MDACC: AML Survival by Decade Patients > 60 ERA N Deaths 1960s 39 39 1970s 166 164 1980s 263 259 1990s 495 461 2000s 486 350 Kantarjian H, O’Brien S . Cancer . 2010;116(21):4896 - 901.
Slide 40: Overall Survival of AML Patients on MRC Trials
Overall Survival of AML Patients on MRC Trials: 1970 to 2004 Burnett, 2012. N = 3,541 N = 7,704 Age 15 - 59 y Age 60+ y
Slide 41: Overall Survival: WCMC
Overall Survival: WCMC N=298 patients, 253 deaths Median OS = 6.5 months (95% CI = 5.1, 8.0)
Slide 42: Survival of Older AML Patients by Therapy
Survival of Older AML Patients by Therapy NA, not applicable. Menzin et al, 2006. Median survival ( mo ) 1 - y survival (%) Overall 4.4 NA Chemotherapy 6.1 ; 30 No therapy 1.7 ; 1 0 o 3,317 elderly patients with AML aged ≥65 years o 1,193 (36%) received chemotherapy (younger, fewer comorbidities) o
Slide 43: Pilot of infusional cytarabine and daunorubicin 7&3
YATES et al: 1973 (!!!!) Pilot of infusional cytarabine and daunorubicin “7&3 DNR45”
Slide 44: Treatment of acute myelocytic leukemia: CALGB study
Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B, Rai et al., Blood 1981 • N = 352, 27 centers, 13 months (1974 - 75): 47 pts < 20 yrs, 105 >60 yrs • Daunorubicin 45 mg/m 2 , ara - C 100 mg/m 2 infusion IVB or CI, 5 or 7 days • 3+7 infusional best regimen • 56% CR Year
Slide 45: Escalation of daunorubicin and addition of etoposide in ADE regimen
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 Baer et al. Leukemia May 2011; 25: 800
Slide 46: UK NCRI AML 14 Trial (Non-Intensive)
Burnett et al. Cancer , 2007; 109: 1114 - 1124. UK NCRI AML 14 Trial (Non - Intensive) Poor - risk karyotype Response Ara - C (N=102) HU (N=99) Induction Death 26% 26% CR 18% 1% Favorable/intermediate - risk karyotype
Slide 47: Intensive vs. Lower-intensity Rx
Intensive vs. Lower - intensity Rx Intensive i) Myelosuppression ii) Extramedullary toxicity iii) Significant induction mortality iv) Prototype: 7&3 What you get for your trouble: Highest response rates Lower - intensity i) Less myelosuppression ii) Less extramedullary toxicity iii) Less induction m
Slide 48: Response Assessment in AML
Response Assessment in AML • Improved complete remission, improved survival • Improved complete remission, no improved survival • No improvement in complete remission, but improved survival
Slide 49: Is there a role for chemotherapy in the era of targeted medicine?
Is there a role for chemotherapy in the era of “targeted” and “personalized” medicine?
Slide 50: Molecular heterogeneity of cytogenetically normal AML
Reprinted with permission. Dohner, H. Blood 2010. Molecular heterogeneity of cytogenetically normal AML
Slide 51: Mutational Complexity of AML
Mutational Complexity of AML Patel et al. NEJM 2012 march 22; 366(12): 1079 - 89.
Slide 52: Targets in Practice
L S D 1 ? ? ? ? I D H 1 T A R G E T P R A C T I C E
Slide 53: Developing CPX-351 Beyond the Initial Indication
D EVELOPING CPX - 351 BEYOND THE INITIAL INDICATION Bruno Medeiros, MD New York, NY July 16, 2015
Slide 54: Future Development of CPX-351
Future Development of CPX - 351 • Current Indication – AML • 60 - 75 years • Fit for conventional induction chemotherapy • High risk patients • Potential Future Indications – AML • High risk AML < 60 years, AML 60 - 75 unfit for induction and AML > 75 years – MDS • Higher risk MDS
Slide 55: High Risk AML <60 Years – Why?
High Risk AML < 60 years – Why? Multifactorial MDR Activity in AML • Delivery – Liposomal encapsulation • Molar ratio – 5:1 cytarabine / dauno • Distribution – Long half life in BM environment
Slide 56: High Risk AML <60 Years – Volume?
High Risk AML < 60 years – Volume? Swedish Acute Leukemia Database Danish Acute Leukemia Database 2000 - 2013 – AML < 60 years – Secondary AML – 17% – Adverse Karyotype – 15% Gunnar J et al. Blood 2012;119:3890 - 3899 Secondary AML – 22% Adverse Karyotype - ?? Østgård L, Medeiros BC et al. JCO, 2015
Slide 57: AML Treatment Algorithm
AML Treatment Algorithm Figure ‘Treatment Algorithm for Older Patients with AML New diagnosis of AML + SAM AML oe AMLMRO) + Blood counts a iaqnone ‘80. Hy pista) ‘tensive treatment Non: + vestoatonal nerany = Hypomatyiting agente Focused geriatric *Low-coao operation ‘assessment or Intensive treatme
Slide 58: AML >60 Years – Why?
First primary AML N=25157 January 1, 2000 - December 31, 2009 N=16765 ≥ 66 years N=13106 Medicare Parts A and B N=8336 Treated within 3 months after diagnosis N=3327 Not Treated N=5009 AML > 66 years – Why? M e deiros BC et al. Ann Hematol. 2015;94 (7):1127 - 38
Slide 59: AML >60 Years – Why?
AML > 66 years – Why? 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2000 (N=868) 2001 (N=845) 2002 (N=959) 2003 (N=880) 2004 (N=848) 2005 (N=824) 2006 (N= 827) 2007 (N= 833) 2008 (N= 820) 2009 (N= 732) Proportion of Patients Year of Diagnosis Not Treated Treated M e deiros BC et al. Ann Hematol. 2015;
Slide 60: Age – Predictor of No Therapy in AML
Age – Predictor of No Therapy in AML p < 0.0001 0 10 20 30 40 50 60 70 80 90 100 66-70 71-75 76-80 > 80 67 55 41 20 33 45 59 80 Proportion of Patients, % Age at Diagnosis Treated Not Treated M e deiros BC et al. Ann Hematol. 2015;94 (7):1127 - 38
Slide 61: AML >60 Years – Why?
AML > 66 years – Why? Log rank p <.0001 Median Survival (95%CI ) Treated: 5.0 months (4.6 - 5.5) Not Treated: 1.7 months (1.6 - 1.8) M e deiros BC et al. Ann Hematol. 2015;94 (7):1127 - 38 Log rank p <.0001
Slide 62: AML Therapy for Unfit Patients
AML Therapy for Unfit Patients J Clin Oncol 2012; 30:2670 - 2677 Decitabine
Slide 63: AML Therapy for Unfit Patients
AML Therapy for Unfit Patients Dombret H et al. EHA, 2014
Slide 64: Myelodysplastic Syndromes
Myelodysplastic Syndromes
Slide 65: Azacitidine in Higher Risk MDS
Azacitidine in Higher Risk MDS 0 5 10 15 20 25 30 35 40 Months From Randomization 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Proportion Surviving CCR VIDAZA Log - rank P =0.0001 HR=0.58 (95% CI: 0.43 - 0.77) 24.5 months 15 months
Slide 66: HMA Failures
HMA Failures Thomas Prébet et al. JCO 2011;29:3322 - 3327
Slide 67: Future Development of CPX-351
Future Development of CPX - 351 CPX - 351 AML < 60 years – High Risk 60 - 75 years – Unfit for conventional chemo >75 years MDS Untreated - Higher Risk HMA Failures
Slide 68: Potential CPX-351 Combinations
Potential CPX - 351 Combinations – Flt3 inhibitors • FLT3 - ITD positive patients – In combination with hypomethylating agents • DNMT3a mutations? • All patients – IDH1 or IDH2 inhibitors – In combination with conjugated MAB • Gemtuzumab • SGN - 33a
Slide 69: Fireside Chat
Fireside Chat Participants: Dr. Gail Roboz , Dr. Bruno Medeiros & Dr. Arthur Louie Moderator: Derek Miller
Slide 70: Paving the Way to CPX-351 Commercialization
Paving the Way to CPX - 351 Commercialization Derek Miller Chief Business Officer
Slide 71: CPX-351 Well-Positioned to Become Foundation of Care in AML
CPX - 351 is Well - Positioned to become the Foundation of Care in AML, which provides an Attractive Commercial Opportunity • No significant improvements to 7+3 in more than 40 years • OS improvement can address large unmet need for AML Patients • Compelling Product Profile (OS, HECON) can Deliver M
Slide 72: Significant Unmet Need in AML
0 10 20 30 40 50 60 70 80 90 0% 20% 40% 60% 80% 100% Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose - Monterey , Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey
Slide 73: AML Induction Therapy Across Risk Categories
AML Induction Therapy Consistent Across Risk Categories with Exception of Unfit Patient Population 73 Celator Pharmaceuticals Source: Results from Hematologist/Oncologist interviews conducted in US and EU (May/June 2014). Induction Therapy Used by Region 100% 100% 100% 100% 20% 20% 6% 11% 18% 27% 29
Slide 74: AML Patients Considered CPX-351 Eligible
AML Patients Initially Considered CPX - 351 - Eligible based on Risk and “Fitness” 74 Celator Pharmaceuticals 60% >60y 40% <60y ~75% Intermediate/High Risk 50% >60y 85% <60y Age “FIT” for Intensive Tx Age based on SEER Incidence for AML. Risk and Fitness based on primary market research CPX - eligib
Slide 75: Clinical Activities Address Populations with Greatest Unmet Needs
Current and Planned Clinical Activities are Designed to Address Intermediate and High Risk Populations with Greatest Unmet Needs 7800 8100 3700 3400 15000 5700 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 >60 1st Line Fit <60 1st Line Fit Relapsed AML Refractory AML Unfit AML High Risk MDS
Slide 76: Global Market Opportunities Support Life Cycle Plans
Global Market Opportunities are Sufficient to Support Life Cycle Plans 76 Celator Pharmaceuticals AML 1L, Int/HR, >60 "Fit" , $450 AML 1L, Int/HR, <60 "Fit" , $300 AML Relapse , $300 AML Refractory , $200 AML 1L all risk, >60 "Unfit" , $400 AML 1L all risk, <60 "Unit" , $100 HR MDS (HMA failure) , $
Slide 77: CPX-351 Potential Positioning
CPX - 351 Potential Positioning* • For Acute Myeloid Leukemia patients who are deemed appropriate to receive intensive myeloablative therapy, CPX - 351 is the foundational treatment that prolongs survival by improving response and reducing treatment - related mortality 77 Celator Pharmaceuticals * F
Slide 78: CPX-351 Value Proposition to Key Stakeholders
CPX - 351 is Poised to Deliver Meaningful Value Proposition to All Key Stakeholders • Prolonged overall survival • Significant reduction in 60 - day early mortality • Higher remission rates could result in more transplant candidates • More convenient and less resource - intensive dosing schedule • 3
Slide 79: Responders May Spend Fewer Days in Hospital vs 7+3
Responders to CPX - 351 May Spend Fewer Days in the Hospital vs 7+3 if Consolidation Therapy is Administered as Outpatient Celator Pharmaceuticals 79 7+3 CPX - 351* Patients, HCPs, Hospitals, and Payers all benefit from less days in the hospital * In study 204, on average, CPX patients had slightly
Slide 80: US Market Served with Lean Infrastructure
US Market Can be Served Effectively and Efficiently with Lean Infrastructure 80 Celator Pharmaceuticals ~ 30 Sales Reps and Managers 50 Centers Performed >70% of AML SCTs States with centers performing >20 AML SCTs in 2014
Slide 81: Investments Made to Prepare for Commercialization
Important Investments Have Been Made to Prepare for Commercialization x KOL and Investigator Engagement • International Advisory Board and ongoing investigator dialogue x Core Scientific Messages x Publication Planning x Developed and Tested Target Product Profile • US and EU (West, Central, East) x
Slide 82: Critical Success Factors to Optimize Launch
Critical Success Factors to Optimize Launch of CPX - 351 • Expand Global Awareness and Experience through Clinical Trials and HCP interactions • Identify Strategic Commercialization Partner • Establish Compelling Value Proposition and Key Supporting Messages • Statistical improvement in Overall Surv
Slide 83: Transform to a Development and Commercial Company
Throughout 2015 - 2016 Celator w ill Transform from a Late - Stage Development Company to a Development and Commercial Company Commercial Partnership Discussions Phase 3 Induction Remission Analysis 2015 2016 Commercial Launch Prep and Positioning CPX - 351 Begin building Commercial Infrastrucure Ph
Slide 84: CPX-351 Well-Positioned to Become Foundation of Care in AML
CPX - 351 is Well - Positioned to become the Foundation of Care in AML, which provides an Attractive Commercial Opportunity • No significant improvements to 7+3 in more than 40 years • OS improvement can address large unmet need for AML Patients • Compelling Product Profile (OS, HECON) can Deliver M
Slide 85: Vyxeos (cytarabine and daunorubicin liposome for injection)
vyxeos cytarabine and duanorubicin liposome for injection celator pharmaceauticals 85
Slide 86: Developing A New Drug or A New Therapy: There is a Difference
Developing A New Drug or A New Therapy: There is a Difference Anthony W. Tolcher MD FRCPC FACP Director of Clinical Research START San Antonio
Slide 87: Magnitude of Benefit
Magnitude of Benefit For single agents, improvement in patient outcomes meeting FDA criteria for approval: • Are often modest survival improvements, PFS, or response • Are rarely, if ever Complete Response or cure Yet, for most patients with cancer, meaningful improvements are likely to come with im
Slide 88: Curative Therapy Came with Cytotoxic Combinations
Curative Therapy with Came with the Advent of Cytotoxic Combinations Hodgkin’s Disease • Individually many chemotherapy agents shrunk disease but not curative until MOPP & ABVD Non - Hodgkin’s Lymphoma • CHOP and then R - RCHOP Testicular Cancer • BEP and EP
Slide 89: Combinations with Molecularly Targeted Agents Have Proven Difficult
Combinations with Molecularly Targeted Agents Have Proven Difficult • Sorafenib , Sunitinib , Pazopanib combinations; very difficult to develop – Too toxic to GI, skin – Dose reductions to very low doses of each agent • mTOR inhibitors – Only combined with endocrine therapy – Too toxic, GI, Skin, me
Slide 90: High Value Combinations
High Value Combinations • High propensity for BRAF, KRAS mutations existing with PIK3Ca, AKT, PTEN mutations • Resistance to BRAFi / MEKi pre - clinically and clinically for PTEN/AKT/PIK3Ca mutations • Preclinical synergy for combining MEKi to mTOR , PI3Ki, AKTi agents
Slide 91: Slide 91
Slide 92: Unable to Deliver Combinations at Full Doses
Unable to Deliver Combinations at Full Doses Toxicity • Stomatitis • skin Activity • HRAS ACC • Few others Dose Reductions Trametinib & GSK 2141795 Toxicity • Skin (Rash) • GI (NVDS) Activity • Melanoma • Breast Dose Reductions Trametinib & Everolimus Tolcher et al CCR 2015 Kurzrock et al ASCO 2011
Slide 93: Unable to Deliver Combinations at Full Doses
Toxicity • Skin (Rash) • GI (NVDS) Activity • KRAS NSCLC • Others Trametinib Afursetinib Tolcher et al 2015 Can Chemo Pharm Toxicity • Skin (Rash) • GI (NVDS) Activity • Endometrial • Ovary • Breast Cobimetinib & Ipatasertib Bendell et al AACR 2014 Unable to Deliver Combinations at Full Doses
Slide 94: Slide 94
Slide 95: Despite Synergy In Preclinical Models
Despite Synergy In Preclinical Models • Synergistic normal tissue toxicity also occurs • Cannot give both drugs at, or near full doses • Antitumor activity has been modest even with biomarker - driven patient selection
Slide 96: To Combine the Two Drugs We Reduce Doses
To Combine the Two Drugs We Reduce Doses… Do We Compromise Each Components Drug Dose & Inhibition of Molecular Target Effectiveness?
Slide 97: Is Sub-Maximal Inhibition of MEK+AKT Better?
Is Sub - Maximal I nhibition of MEK+AKT Better than Maximal I nhibition of E ither MEK or AKT Inhibitors Alone? Mutations 50 MEK + 50 AKT Vs 100% MEK (number of cell lines) 75 MEK + 75 AKT Vs 100% MEK (number of cell lines) 50 MEK + 50 AKT Vs 100% AKT (number of cell lines) 75 MEK + 75 AKT Vs 100% A
Slide 98: Is Sub-Maximal Inhibition of MEK+AKT Better? Conclusions
Is Sub - Maximal I nhibition of MEK+AKT Better than Maximal I nhibition of E ither MEK or AKT Inhibitors Alone? Conclusions In BRAF mutant cell lines, reducing dose of MEK inhibitor to add AKT is inferior to full dose MEK If PIK3CA mutant, reducing dose of AKT inhibitor, to add MEK is inferior to fu
Slide 99: Many More Challenges to Come
Many More Challenges to Come CDK4/6 inhibitors (e.g. Palbociclib ) • Tolerable with endocrine therapy but diarrhea and neutropenia mean combinations will be difficult FGFR inhibitors (many) • GI, liver function, and phosphorous alterations BET Inhibitors (many)
Slide 100: If we compromise the dose(s), we compromise the benefit
If we compromise the dose(s), we compromise the benefit T herapeutic index of combinations is low: • Prevents full dose of both agents • Diminishes therapeutic benefit, leading to increased risk of clinical trial failure • How can we ensure coordinated inhibition of combined targets without causing
Slide 101: How Do We Improve Therapeutic Index?
How Do We Improve Therapeutic Index? Combination of non - cross - toxic agents • Basis of cytotoxic combinations, e.g vincristine with alkylator Preferential Delivery to tumor vs normal tissue • Basis of Antibody Drug Conjugate platform; utility for coordinated combination therapies unknown • Celato
Slide 102: Conclusions
Conclusions • Developing combinations of potentially synergistic combinations must continue to achieve clinically meaningful therapies • If synergistic toxicities occur, we must explore new delivery systems • Preferential delivery to tumor over normal tissue is necessary for many of the high value c
Slide 103: CombiPlex Technology Platform: Application to Molecularly Targeted Agent Combinations
CombiPlex Technology Platform Application to Molecularly Targeted Agent Combinations
Slide 104: Rationale for CombiPlex in Targeted Agent Combinations
Celator Pharmaceuticals Rationale for CombiPlex ® in the Development of Targeted Agent Combinations • Single molecularly targeted agents often have modest or transient antitumor activity • Individual targets rarely dictate tumor cell survival independently • Inter - pathway communication and feedbac
Slide 105: Traditional Approach Fails to Optimize Combination Regimens
Traditional Approach Fails to Optimize Combination Regimens Many drug combinations require simultaneous exposure, however: • Combining drugs at ratios based on MTD may be antagonistic and/or more toxic • Even if a synergistic ratio is identified , it will be lost without a delivery vehicle due to PK
Slide 106: Unwanted Exposure to Healthy Tissue and Changing Drug Ratios
Celator Pharmaceuticals Unwanted Exposure to Healthy Tissue and Changing Drug Ratios are Typical for Conventional Combinations • Significant drug exposure to healthy tissues leads to toxicity problems • Drug elimination from body occurs rapidly after administration stops and varies between drugs • V
Slide 107: The CombiPlex Solution: True Combination Products
The CombiPlex ® Solution: True Combination Products Celator Pharmaceuticals 106 • Identify molar synergy in vitro • Lock optimal ratio in a delivery complex • Nano - scale liposomes and nanoparticles engineered to: • Stably encapsulate drug ratios • Harmonize PK through controlled release to maintai
Slide 108: CombiPlex Solves the Coordinated Exposure Problem
Celator Pharmaceuticals CombiPlex ® Solves the Coordinated Exposure Problem for Drug Combinations • Markedly reduced drug exposure to healthy tissues reduces toxicity problems and increases exposure to tumor tissue • Drug elimination occurs slowly and at the same rate for both drugs • CombiPlex gets
Slide 109: Targeted Agent Combinations Selected for CombiPlex
Celator Pharmaceuticals 108 Molecularly Targeted Agent Combinations Selected for CombiPlex ® Application Combinations of epigenetic modulators • Histone deacetylase inhibitors ( vorinostat ); plus • Hypomethylating agents (e.g. decitabine ) Combinations targeting major signaling pathways • Inhibitor
Slide 110: Nanoparticle-Based CombiPlex Systems: Hydrophobic Prodrug Nanoparticles
Celator Pharmaceuticals Nanoparticle - Based CombiPlex ® Systems: Hydrophobic Prodrug Nanoparticles (HPN) • Used to control the PK of hydrophobic drugs; most targeted agents are hydrophobic • Anchor and linker chemistry of prodrugs controls release of parent drug • Iterative process of structure - p
Slide 111: HPN Formulation Development Flowchart
HPN Formulation Development Flowchart Excipient and Solvent Evaluation • Selection of well - characterized diblock polymers such as PEG - PLA, PEG - PCL, PEG - PS, PEG - PLGA for different degrees of hydrophobicity and crystallinity • Optimization of copolymer block lengths to achieve good drug load
Slide 112: CombiPlex Optimizing Combinations: Docetaxel + HSP90 inhibitor
Issues CombiPlex ® Optimizing Combinations of Molecularly Targeted Agents: Docetaxel + HSP90 inhibitor (AUY922) 111 Docetaxel plus HSP90 inhibitors PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK HDAC inhibitors plus Hypomethylating agents Concurrent and prolonged exposure required for optimal efficacy Pathw
Slide 113: HPN Formulation of Docetaxel:AUY922 Increases Plasma Drug Concentrations
Celator Pharmaceuticals 112 HPN Formulation of Docetaxel:AUY922 Dramatically Increases Plasma Drug Concentrations and Coordinates PK Compared to Free Drugs Plasma concentrations of AUY922 and docetaxel in nanoparticle formulation are more than 2 - 4 orders of magnitude greater than conventional IV f
Slide 114: Docetaxel:AUY922 Free Drug Combination Must Reduce Dose
Celator Pharmaceuticals 113 Docetaxel:AUY - 922 Free Drug Combination Must Reduce Dose of Individual Agents Markedly Compared to CombiPlex ® Formulation % Free Drug MTD 0 20 40 60 80 100 Docetaxel MTD AUY922 MTD Free Drug Combination Nanoparticle Combination Maximum tolerated dose (MTD*) of Docetaxe
Slide 115: Efficacy of Docetaxel:AUY922 in HCT15 Tumor Model
Efficacy of Docetaxel:AUY922 in the HCT15 Tumor Model ( Taxane Resistant Model) Celator Pharmaceuticals 114 Nanoparticle formulation of Docetaxel and AUY922 is more efficacious than the free drug combination in a taxane resistant colorectal cancer model Days After Treatment 0 10 20 30 40 50 Tumor Vo
Slide 116: Efficacy of Docetaxel:AUY922 in ST996 PDX Tumor Model
Days After Administration 0 5 10 15 20 25 30 35 Cubic Millimeters 0 200 400 600 8001000 1200 1400 1600 1800 Saline Control Nanoparticle DOC:AUY (10:20 mg/kg) Nanoparticle DOC:AUY (20:40 mg/kg) Efficacy of Docetaxel:AUY922in the ST996 PDX Tumor Model ( Taxane Resistant Model) Celator Pharmaceuticals
Slide 117: Efficacy of Docetaxel:AUY922 in HCC1569 Tumor Model
Days After Administration -5 0 5 10 15 20 25 30 Tumor Size (cubic millimeters) 0 1000 2000 3000 4000 Saline Control Nanoparticle DOC:AUY (20:40 mg/kg) Efficacy of Docetaxel:AUY922 in the HCC1569 Tumor Model ( Taxane Sensitive Model) Celator Pharmaceuticals 116 Nanoparticle formulation of Docetaxel a
Slide 118: CombiPlex Optimizing Combinations: MEK inhibitor + Akt inhibitor
Issues CombiPlex ® Optimizing Combinations of Molecularly Targeted Agents: MEK inhibitor ( S elumetinib ) + Akt inhibitor ( Ipatasertib ) 117 Docetaxel plus HSP90 inhibitors PI3K/AKT/mTOR plus Ras/Raf/MEK/ERK HDAC inhibitors plus Hypomethylating agents Concurrent and prolonged exposure required for
Slide 119: HPN Formulation of Selumetinib:Ipatasertib Increases Plasma Drug Concentrations
Celator Pharmaceuticals 118 HPN Formulation of Selumetinib:Ipatasertib Dramatically Increases Plasma Drug Concentrations and Coordinates PK Compared to Free Drug Hours After Injection 0 5 10 15 20 25 Percent Injected Dose 0.01 0.1 1 10 100 1000 Nano Selumetinib Nano Ipatasertib Oral Selumetinib Exte
Slide 120: Improved Tolerability of Selumetinib:Ipatasertib Formulation
Celator Pharmaceuticals 119 Improved Tolerability of CombiPlex Formulation of Selumetinib:Ipatasertib Compared to the Free Drug Combination Maximum tolerated dose ( MTD) of Ipatasertib administered as a combination was compared to the MTD of free drug administered individually* *Note that bioavailab
Slide 121: Ongoing/Future Studies with Targeted Agent Combinations
Celator Pharmaceuticals 120 Ongoing/Future Studies with Combinations Utilizing Molecularly Targeted Agents • Numerous efficacy studies with nanoparticle formulations ongoing • Drug ratio optimization in nanoparticle • Efficacy vs free drug combinations • Individual vs combination agents • Characteri
Slide 122: HPN Formulation of Selumetinib and Docetaxel Exhibits Coordinated PK
Hours After Administration 0 5 10 15 20 25 Percent Injected Dose 1 10 100 Nano Selumetinib Nano Docetaxel Celator Pharmaceuticals 121 HPN Formulation of Selumetinib and Docetaxel Exhibits Coordinated PK: Demonstrates “Modular” Properties of HPN Platform Plasma concentrations of Selumetinib and Docet
Slide 123: CombiPlex Optimizing Combinations: Hypomethylator + HDAC inhibitor
Issues CombiPlex ® Optimizing Combinations of Molecularly Targeted Agents: Hypomethylator ( Decitabiine ) + HDAC inhibitor ( Vorinostat ) 122 Docetaxel plus HSP90 inhibitors PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK HDAC inhibitors plus Hypomethylating agents Concurrent and prolonged exposure required
Slide 124: CombiPlex Formulation Development of Decitabine:Vorinostat
Celator Pharmaceuticals 123 CombiPlex ® Formulation Development of Decitabine:Vorinostat • Decitabine degrades under conditions required for liposome encapsulation • Hydrophobic prodrugs of decitabine and vorinostat were synthesized and incorporated into nanoparticles • Numerous formulations prepare
Slide 125: CombiPlex Platform R&D Summary
Celator Pharmaceuticals 124 CombiPlex ® Platform R&D Summary • CombiPlex technology can be applied to a range of molecularly targeted agents • Hydrophobic prodrug nanoparticle (HPN) platform is well suited for optimizing and coordinating PK of targeted agent combinations • Nanoparticle delivery mark
Slide 126: Upcoming Activities and Milestones of Note
Celator Pharmaceuticals 125 Upcoming Activities and Milestones of Note • Full data packages available end of 3Q 2015 • Formulation and pharmaceutical stability • Pharmacokinetics • Tolerability + selected target organ toxicity testing • Efficacy vs free drug in multiple tumor models + drug ratio dep
Slide 127: Question and Answer Session
Question and Answer Session - Technology Platform - General
Slide 128: Closing Remarks
Closing Remarks Scott Jackson Chief Executive Officer
Slide 129: Exciting Future for Celator: Creating Shareholder Value
Exciting Future for Celator Establishing CPX - 351 as a new foundation of care for AML patients • Phase 3 study - going head - to - head against the 7+3 regimen • Preparing for a NDA submission in 3Q2016 • Commercialization activities are underway • Expanding clinical development to demonstrate broa
Slide 130: 2015-2016 Selected News Flow and Expected Milestones
Fast Track Designation 2015 - 2016 Selected News Flow and Expected Milestones Potential NDA Filing in 3Q2016 Phase 3 Induction Remission Rate First Relapse Phase 2 Publication 2015 2016 AACR abstracts ASH abstracts AACR abstracts ASCO abstracts ASH abstracts Technology Platform Programs – data packa
Slide 131: Transform to a Development and Commercial Company
Throughout 2015 - 2016 Celator w ill Transform from a Late - Stage Development Company to a Development and Commercial Company Commercial Partnership Discussions Phase 3 Induction Remission Analysis 2015 2016 Commercial Launch Prep and Positioning CPX - 351 Begin building Commercial Infrastrucure Ph
Slide 132: Thank You!
131 NASDAQ:CPXX | celatorpharma.com Thank You ! © Copyright 2015 Celator Pharmaceuticals. All rights reserved.